Every 10-Q that Tempest Therapeutics Inc (TPST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TPST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TPST filings page.
Tempest Therapeutics, Inc. is a clinical-stage biotech focused on CAR‑T therapies, now centered on TPST‑4003, an in vivo CD19/BCMA CAR‑T candidate for autoimmune and oncology indications. In February 2026 it acquired four Erigen CAR‑T programs, issuing 8,268,495 shares; the $22.2 million total cost was expensed as acquired in‑process R&D, driving a sharp increase in loss.
For the six months ended June 30, 2026, Tempest reported a net loss of $32.9 million versus $18.7 million a year earlier, and a stockholders’ deficit of $1.1 million compared with equity of $6.7 million at year‑end 2025. Cash and cash equivalents were only $0.8 million, and management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months.
Liquidity actions include a $20 million Funding Commitment from Factor Bioscience (with $11.8 million remaining availability), a March 2026 private placement raising about $2.0 million, and a May 2026 warrant‑exercise inducement raising a further $2.0 million. A warrant dividend distributed 6,784,989 equity warrants, and subsequent to quarter‑end Tempest arranged an equity purchase facility with Lincoln Park Capital for up to $50 million, subject to conditions.
Tempest Therapeutics reported a much wider quarterly loss as it reshaped its business around CAR‑T assets. For the three months ended March 31, 2026, net loss was $27.7 million, driven largely by $22.2 million of acquired in‑process research and development expense tied to the Erigen CAR‑T asset acquisition. Core research and development spending dropped sharply to $0.1 million as prior programs were wound down, while general and administrative costs rose to $5.4 million on deal and transaction-related expenses.
Cash and cash equivalents fell to $1.8 million from $7.7 million at year‑end, and management states there is substantial doubt about the company’s ability to continue as a going concern without new funding. Tempest completed a roughly $2.0 million private placement and has a funding commitment of up to $20.0 million from Factor Bioscience, with $13.8 million remaining, but access depends on meeting specified conditions. The company also issued 6.78 million equity warrants as a dividend and completed an 8.27 million‑share stock issuance to acquire the TPST‑2003 CAR‑T portfolio, significantly increasing its share count to 14.3 million outstanding at quarter‑end.
Tempest Therapeutics (TPST) filed its Q3 2025 report, highlighting constrained liquidity and a strategic review. Cash and cash equivalents were $7.5 million with total assets of $17.1 million and stockholders’ equity of $6.3 million as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, noting existing cash is expected to fund operations for less than 12 months from the financial statement issuance date.
Quarterly net loss was $3.5 million versus $10.6 million a year earlier, driven by a sharp reduction in research and development to $0.6 million from $7.6 million amid the workforce reduction and paused programs during the strategic review. General and administrative expenses were $3.0 million, roughly flat year over year.
Financing actions included a registered direct offering delivering net proceeds of $4.1 million and ATM sales totaling $2.8 million year-to-date. The Oxford term loan was fully repaid for $3.5 million in April, releasing all liens. A one-for-thirteen reverse stock split was effected in April. Programs include amezalpat, cleared to begin a pivotal Phase 3 in HCC with FDA Fast Track and Orphan Drug designations, and TPST-1495, slated for an NCI-funded Phase 2 in FAP.
Tempest Therapeutics is a clinical-stage oncology company advancing two lead programs while conducting a strategic review to extend limited cash resources. The lead candidate, amezalpat, is positioned to begin a pivotal Phase 3 trial in first-line hepatocellular carcinoma and has received regulatory momentum including FDA Orphan Drug and Fast Track designations, a favorable end-of-Phase 2 meeting, and agency clearances to proceed in the U.S. and China; the company also reported EMA Orphan Drug designation. The second program, TPST-1495, received FDA authorization for an NCI-supported Phase 2 study in FAP and an FDA Orphan Drug designation.
Financially, Tempest reported $14.3 million in cash and cash equivalents and an accumulated deficit of $225.8 million. Net loss was $18.7 million for the six months ended June 30, 2025. The company expects existing cash to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern. In April 2025 Tempest launched a strategic alternatives process, reduced headcount (21 of 26 employees), transitioned key executives to consulting arrangements, completed a registered direct offering that raised net proceeds of ~$4.1 million, sold ~$2.8 million of stock via its ATM program year-to-date, and repaid its term loan in April 2025.